Showing results (401-410 of 449) with videos related to
Sort By:
Pageof 45
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2015
Targeting MYCN-Driven Transcription By BET-Bromodomain InhibitionAnton Henssen, Kristina Althoff, Andrea Odersky, et al.British Journal of Cancer|February 22, 2023
Genomic ALK alterations in primary and relapsed neuroblastomaCarolina Rosswog, Jana Fassunke, Angela Ernst, et al.Pharmacological Research|January 19, 2025
Targeting MYCN upregulates L1CAM tumor antigen in MYCN-dysregulated neuroblastoma to increase CAR T cell efficacyLaura Grunewald, Lena Andersch, Konstantin Helmsauer, et al.Der Urologe. Ausg. A|January 15, 2009
[Complete resection of urothelial cancer metastases with curative intent]J Lehmann, H Suttmann, P Albers, et al.Nature Genetics|August 19, 2020
Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancersHoon Kim, Nam-Phuong Nguyen, Kristen Turner, et al.Molecular Cancer Therapeutics|December 30, 2023
Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor ModelsFabian F Pusch, Heathcliff Dorado García, Robin Xu, et al.Oncotarget|December 10, 2015
Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastomaAnneleen Decock, Maté Ongenaert, Robrecht Cannoodt, et al.EJC Paediatric Oncology|March 10, 2025
Adjuvant therapy for children treated by enucleation at diagnosis of retinoblastomaYelena Diarra, Christina Brockmeyer, Karen Fischhuber, et al.Science Translational Medicine|July 6, 2012
Targeted expression of mutated ALK induces neuroblastoma in transgenic miceLukas C Heukamp, Theresa Thor, Alexander Schramm, et al.Nature Communications|November 24, 2021
Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisionsKarin Schmelz, Joern Toedling, Matt Huska, et al.Pageof 45